Compare ENTX & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | INTT |
|---|---|---|
| Founded | 2010 | 1981 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 234.0M |
| IPO Year | 2015 | 1997 |
| Metric | ENTX | INTT |
|---|---|---|
| Price | $1.66 | $15.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 2.7M | 267.6K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | 0.06 |
| Revenue | $42,000.00 | ★ $66,801,000.00 |
| Revenue This Year | N/A | $15.82 |
| Revenue Next Year | N/A | $9.10 |
| P/E Ratio | ★ $23.71 | $261.67 |
| Revenue Growth | N/A | ★ 66.06 |
| 52 Week Low | $0.91 | $6.63 |
| 52 Week High | $3.22 | $20.00 |
| Indicator | ENTX | INTT |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 43.20 |
| Support Level | $1.45 | $14.89 |
| Resistance Level | $1.94 | $19.64 |
| Average True Range (ATR) | 0.26 | 1.32 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 31.29 | 12.11 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.